Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COGNEX CORPCGNX · Entity 3527 | EVP, Global Sales and Products | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COGNEX CORP
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-02-23 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-02-20 · Exercise / conversion · Acquired 6,846 · Balance 10,650 Row 2 · 2026-02-20 · Tax withholding · Disposed 2,010 · Balance 8,640 F1: This disposition represents shares withheld to satisfy tax withholding obligations on the restricted stock units that vested on February 20, 2026 and are reported herein. Row 3 · 2026-02-20 · Sale · Disposed 3,804 · Balance 4,836 F2: These shares were disposed of in an open market sale pursuant to a trading plan adopted by the reporting person in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Row 4 · 2026-02-21 · Exercise / conversion · Acquired 8,791 · Balance 13,627 Row 5 · 2026-02-21 · Tax withholding · Disposed 3,095 · Balance 10,532 F3: This disposition represents shares withheld to satisfy tax withholding obligations on the restricted stock units that vested on February 21, 2026 and are reported herein. Row 6 · 2026-02-23 · Sale · Disposed 10,532 · Balance 0 F2: These shares were disposed of in an open market sale pursuant to a trading plan adopted by the reporting person in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2026-02-21 | Direct | 0 |
Reported balance
After 2026-02-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-21 · Exercise / conversion · Disposed 8,791 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Cognex Corporation common stock. F5: The restricted stock units vest approximately 20%, 30%, and 50% on the first, second, and third anniversaries of the grant date (February 21, 2023), respectively. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-02-20 | Direct | 11,410 |
Reported balance
After 2026-02-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-20 · Exercise / conversion · Disposed 6,846 · Balance 11,410 F4: Each restricted stock unit represents a contingent right to receive one share of Cognex Corporation common stock. F6: The restricted stock units vest approximately 20%, 30%, and 50% on the first, second, and third anniversaries of the grant date (February 20, 2024), respectively. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2028-02-18 | Direct | 22,276 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 22,276 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-17 | Direct | 24,085 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 24,085 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.04 · Expires 2035-02-18 | Direct | 75,871 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 75,871 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.44 · Expires 2034-02-20 | Direct | 126,800 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 126,800 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.21 · Expires 2033-02-21 | Direct | 94,298 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 94,298 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.94 · Expires 2030-02-18 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 80,000 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.49 · Expires 2029-02-19 | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 60,000 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.44 · Expires 2028-02-20 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 20,000 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.09 · Expires 2036-02-17 | Direct | 24,854 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 24,854 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.43 · Expires 2032-02-22 | Direct | 74,720 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 74,720 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.90 · Expires 2030-10-30 | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2026-02-20 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 150,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This disposition represents shares withheld to satisfy tax withholding obligations on the restricted stock units that vested on February 20, 2026 and are reported herein.
F2: These shares were disposed of in an open market sale pursuant to a trading plan adopted by the reporting person in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F3: This disposition represents shares withheld to satisfy tax withholding obligations on the restricted stock units that vested on February 21, 2026 and are reported herein.
F4: Each restricted stock unit represents a contingent right to receive one share of Cognex Corporation common stock.
F5: The restricted stock units vest approximately 20%, 30%, and 50% on the first, second, and third anniversaries of the grant date (February 21, 2023), respectively.
F6: The restricted stock units vest approximately 20%, 30%, and 50% on the first, second, and third anniversaries of the grant date (February 20, 2024), respectively.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2021 Filed Feb 24, 2021 15:21 UTC | COGNEX CORP CGNX · Entity 3527 | SaleCommon Stock | 30,000 | $82.76 | $2,482,731.00 |
DisclosureSEC source: 0001829813-21-000002 · edgardoc.xml · nonDerivative · entry 4 Gerst Carl · CIK 0001829813 · EVP, Vision & ID Products 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 15:21 UTC | COGNEX CORP CGNX · Entity 3527 | Exercise / conversionCommon Stock | 30,000 | $56.44 | $1,693,200.00 |
DisclosureSEC source: 0001829813-21-000002 · edgardoc.xml · nonDerivative · entry 3 Gerst Carl · CIK 0001829813 · EVP, Vision & ID Products 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 15:21 UTC | COGNEX CORP CGNX · Entity 3527 | SaleCommon Stock | 25,000 | $82.76 | $2,068,942.50 |
DisclosureSEC source: 0001829813-21-000002 · edgardoc.xml · nonDerivative · entry 2 Gerst Carl · CIK 0001829813 · EVP, Vision & ID Products 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 23, 2021 Filed Feb 24, 2021 15:21 UTC | COGNEX CORP CGNX · Entity 3527 | Exercise / conversionCommon Stock | 25,000 | $38.39 | $959,750.00 |
DisclosureSEC source: 0001829813-21-000002 · edgardoc.xml · nonDerivative · entry 1 Gerst Carl · CIK 0001829813 · EVP, Vision & ID Products 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 15:30 UTC | COGNEX CORP CGNX · Entity 3527 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $65.90 | $0.00 |
DisclosureSEC source: 0001829813-20-000004 · edgardoc.xml · derivative · entry 2 Gerst Carl · CIK 0001829813 · EVP, Vision & ID Products 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 100,000 shares Expires 2030-10-30 Read SEC document |
| October 30, 2020 Filed Nov 2, 2020 15:30 UTC | COGNEX CORP CGNX · Entity 3527 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $65.90 | $0.00 |
DisclosureSEC source: 0001829813-20-000004 · edgardoc.xml · derivative · entry 1 Gerst Carl · CIK 0001829813 · EVP, Vision & ID Products 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-10-30 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.